StopDown
Biodeal Pharmaceuticals logo
Funding · 10 August 2026Biodeal Pharmaceuticals₹385 croreContract development and manufacturing organisationbiodealpharma.com ↗

Biodeal raises ₹385 crore from RMB Capitalworks

By · Editor ·

growthNoidaFounded 2005
  • Biodeal Pharmaceuticals is a CDMO that manufactures drugs and formulations for global pharma brands
  • It raised ₹385 crore from RMB Capitalworks, its first equity raise in two decades
  • The funds will be used for business expansion and R&D for new molecules, targeting ₹500 crore revenue in FY27

What happened

  • Biodeal Pharmaceuticals announced a ₹385 crore investment from RMB Capitalworks, a unit of South African lender FirstRand Bank.
  • This is the first equity raise by Biodeal in its two-decade history.
  • The stake acquired by RMB Capitalworks is undisclosed.
  • RMB Capitalworks Managing Partner is Anshuman Malur.
  • The funds will be used for business expansion and R&D for new molecules.
  • Biodeal plans to expand into new segments.
  • The company reported FY26 revenue of ₹325 crore with an operating profit margin of 20%.
  • It targets FY27 revenue of ₹500 crore and FY30 revenue of ₹1,200 crore.

Why it matters

  • Biodeal has been bootstrapped for 20 years and is now raising external capital for the first time.
  • The investment comes from a South African financial group, indicating cross-border interest in Indian pharma CDMOs.
  • The company's revenue target of ₹1,200 crore by FY30 suggests a 3.7x growth plan over four years.

The business

  • Biodeal Pharmaceuticals is a contract development and manufacturing organisation (CDMO).
  • It serves 500+ pharma companies across 80+ countries.
  • The company has developed 1,000+ formulations and holds 30+ accreditations including WHO-GMP, PIC/S, ISO, Health Canada, and AYUSH.
  • It operates 10 manufacturing blocks across two factories in Himachal Pradesh.
  • Production capacity includes 3 billion tablets/year, 650 million capsules/year, and 30 million nasal spray units/year.
  • Biodeal is a pioneer in nasal spray and DPI manufacturing in India and manufactures Allegra Nasal for Sanofi.
  • It has four verticals: Pharmaceuticals, Derma & Cosmetics, Nutraceuticals, and Herbaceuticals.
  • The company has 1,200+ employees and 35 R&D scientists in DSIR-approved labs.
  • It offers four engagement models: Contract Manufacturing, Loan Licensing, R&D, and Nasal & DPI Systems.

The founders

Anurag Kumar

Chairman and Managing Director
in
  • Anurag Kumar is the Chairman and Managing Director of Biodeal Pharmaceuticals.
  • He has led the company since its founding in 2005.

Who put in money

  • RMB Capitalworks lead — RMB Capitalworks is a unit of South African lender FirstRand Bank, led by Managing Partner Anshuman Malur.

In numbers

₹325 croreFY26 revenue
20%FY26 operating profit margin
₹500 croreFY27 revenue target
₹1,200 croreFY30 revenue target
500+Pharma companies served
80+Countries served
1,000+Formulations developed
30+Accreditations
10Manufacturing blocks
1,200+Employees
3 billion/yearTablet production capacity
650 million/yearCapsule production capacity
30 million units/yearNasal spray production capacity
35R&D scientists

What happens next

  • Biodeal will use the funds for business expansion and R&D for new molecules.
  • The company plans to expand into new segments.
  • It targets ₹500 crore revenue in FY27 and ₹1,200 crore by FY30.

Up against

Laurus LabsDivis LaboratoriesPiramal Pharma SolutionsSyngene International

Words to know

CDMO
Contract Development and Manufacturing Organisation – a company that provides drug development and manufacturing services to other pharmaceutical companies on a contract basis.
DPI
Dry Powder Inhaler – a device that delivers medication in powder form to the lungs, used for respiratory conditions like asthma.
WHO-GMP
World Health Organization Good Manufacturing Practices – international quality standards for pharmaceutical production.
PIC/S
Pharmaceutical Inspection Co-operation Scheme – a set of quality standards for pharmaceutical manufacturing used by regulatory authorities worldwide.

The numbers around it

Healthcare & Life Sciences in August 2026: 10 rounds with a disclosed amount, $139 million in all; the biggest was Biodeal Pharmaceuticals (₹385 crore). Every sector this year →

Read it as a card in the app

Terms in this story

  • Financial year: An Indian financial year runs from 1 April to 31 March, and it is named after the year it ends. FY26 means April 2025 to March 2026. Startup results for a year arrive months after it closes, so a November 2026 story may still be about FY25.

Everything on Biodeal Pharmaceuticals → · All startup news on 10 August 2026 →

Is this Biodeal Pharmaceuticals? Get your “Featured on StopDown” badge →